Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 26.88
Key Takeaways
Risk factor
Low price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E, undervalued on EV/EBITDA, underpriced on P/F
Data is available to registered users only
